



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07C 249/00, 263/00	A1	(11) International Publication Number: WO 94/14758 (43) International Publication Date: 7 July 1994 (07.07.94)
(21) International Application Number: PCT/US93/12480 (22) International Filing Date: 20 December 1993 (20.12.93) (30) Priority Data: 07/995,585 22 December 1992 (22.12.92) US (71) Applicant: ENZON, INC. [US/US]; 40 Kingsbridge Road, Piscataway, NJ 08854 (US). (72) Inventor: GREENWALD, Richard, B.; 113 Hickory Road, Somerset, NJ 08873 (US). (74) Agents: MERCANTI, Michael, N. et al.; Enzon, Inc., 40 Kingsbridge Road, Piscataway, NJ 08854 (US).		(81) Designated States: AU, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, NO, NZ, PL, RO, RU, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: ARYL IMIDATE ACTIVATED POLYALKYLENE OXIDES (57) Abstract Water-soluble aryl imidate activated polyalkylene oxides having improved hydrolytic stability and conjugates of the aryl imidate activated polyalkylene oxides with biologically active nucleophiles are disclosed. Methods of preparing the activated polyalkylene oxides and conjugates thereof are also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ARYL IMIDATE ACTIVATED POLYALKYLENE OXIDES

5

BACKGROUND OF THE INVENTION

The present invention relates to aryl imidate activated polyalkylene oxides having improved hydrolytic stability, and to water-soluble polyalkylene oxide conjugates prepared therefrom.

10

The conjugation of water-soluble polyalkylene oxides with useful molecules such as proteins and polypeptides is well known. The coupling of peptides and polypeptides to polyethylene glycol (PEG) and similar water-soluble polyalkylene oxides is disclosed by U.S. Patent No. 4,179,337 to Davis et al.

15

Davis et al. discloses that physiologically active polypeptides modified with PEG exhibit dramatically reduced immunogenicity and antigenicity. Also, the polyalkylene oxide conjugates, when injected into a living organism, have been shown to remain in the bloodstream considerably longer than the corresponding native proteins. Accordingly, a number of polyalkylene oxide conjugated therapeutic proteins have been developed exhibiting reduced immunogenicity and antigenicity and longer clearance times, while retaining a substantial portion of the protein's physiological activity.

20

25

Significant polyalkylene oxide conjugated therapeutic proteins include tissue plasminogen activator, insulin, interleukin II and hemoglobin.

30

The utility of polyalkylene oxide conjugation is not limited to the modification of proteins and polypeptides. Activated polyalkylene oxides will react with essentially any nucleophile. The coupling of polyalkylene oxides with oligonucleotides is disclosed by U.S. Patent No. 4,904,582 to Tullis. U.S. Patent No. 5,160,734 discloses sustained release formulations of polyalkylene oxides

35

coupled with dihydropyridine calcium channel blockers.

To conjugate polyalkylene oxides, the hydroxyl end-groups of the polymer must first be converted into, that is, substituted with, reactive functional groups.

5 This process is frequently referred to as "activation" and the product is called an "activated polyalkylene oxide."

Until recently, covalent attachment of the polyalkylene oxide to an appropriate nucleophile was effected by activated polyalkylene oxides such as polyalkylene oxide succinoyl-N-hydroxy succinate, as disclosed by Abuchowski et al., Cancer Biochem. Biophys., 7, 175-86 (1984). This polyalkylene oxide derivative is desirable because it is reactive under mild conditions.

15 A shortcoming associated with this derivative, however, is the fact that it is relatively hydrolytically unstable when no nucleophile is present. Recently, in U.S. Patent No. 5,122,614, polyalkylene oxide-N-succinimide carbonates were disclosed having improved hydrolytic stability over the polyalkylene oxide succinoyl succinates. Even so, these active esters undergo hydrolysis under the pH conditions necessary to deprotonate the epsilon-NH₂ groups of polypeptide lysines for conjugation, which subject the activated polyalkylene oxide to hydroxyl attack. This does not affect the reaction end product, other than to reduce its yield. While reduced yields ordinarily affect product cost, the hydrolysis becomes even more costly for several reasons. Firstly, reaction mixtures cannot be prepared significantly in advance. Additional purification of the end product is required to remove the hydrolytic degradation products. Furthermore, the reduction in yield is compensated for by increasing the amount of activated polyalkylene oxide starting material. This

increases the viscosity of the reaction mixture, thereby further increasing the processing cost, and potentially interferes with downstream purification of the polymer and conjugate.


5 There remains a need for hydrolytically stable activated polyalkylene oxides. One group of newly developed polyalkylene oxides is the polyalkylene oxide alkyl imidates of U.S. Patent No. 4,791,192. However, Hunter et al., J. Amer. Chem. Soc., 84, 3491-504 (1962)
10 and Browne et al., Biochem. and Biophys. Res. Comm., 67(1), 126-32 (1975) studied the use of simple alkyl imidates to modify the primary amines of proteins and other small molecules and reported the alkyl imidates to be hydrolytically unstable at protein reaction
15 conditions. Hunter et al., however, reported simple aryl imidates to be hydrolytically stable. Aryl imidate activated polyalkylene oxides are unreported.

SUMMARY OF THE INVENTION

20 It has now been discovered that polyalkylene oxides activated by substitution with an aryl imidate moiety possess a desirable combination of nucleophilic reactivity and hydrolytic stability. For the conjugation of polyalkylene oxides with polypeptides, the desired
25 aminolysis predominates over hydrolysis, so that reactions with proteins in aqueous solutions occur with higher yields. The aryl imidate activated polyalkylene oxides have improved resistance to hydroxyl attack under the pH conditions which are required in order to
30 deprotonate the protein amines.

Therefore, in accordance with the present invention there is provided a water-soluble aryl imidate activated polyalkylene oxide. Preferred aryl imidate activated polyalkylene oxides are represented by the structure of

Formula I:



5

wherein R is a water-soluble polyalkylene oxide;

L is a moiety forming a hydrolytically stable, covalently bonded linkage between the polyalkylene oxide and the phenyl ring of the aryl imidate;

10 R_1 is a moiety selected from alkyl, phenyl, phenylalkyl and cycloalkyl moieties; and

X is a terminal moiety of the polyalkylene oxide.

In accordance with the present invention, there is also provided a process for the preparation of water-soluble aryl imidate activated polyalkylene oxides, which process includes the steps of:

reacting a benzonitrile-capped poly-alkylene oxide with an alcohol in the presence of anhydrous hydrogen chloride gas, so that an aryl imidate activated polyalkylene oxide is formed; and

20 recovering said aryl imidate activated polyalkylene oxide.

The aryl imidate activated polyalkylene oxides of the present invention react with biologically active nucleophiles to form conjugates thereof covalently bonded by linkages containing imino moieties. When the biologically active nucleophile is a protein or polypeptide, conjugation occurs at the epsilon-NH₂ moieties of lysines to form a linkage containing a stable amidate moiety.

30 The present invention therefore also provides a method of forming a biologically active conjugate of a biologically active nucleophile and one or more water-soluble polyalkylene oxides covalently bonded

thereto, which method includes the steps of:

contacting the nucleophile with an aryl imidate activated polyalkylene oxide, so that a biologically active conjugate of the biologically active nucleophile and the polyalkylene oxide is formed; and

recovering the biologically active conjugate.

The present invention thus also provides a biologically active conjugate of a nucleophile having biological activity and one or more water-soluble polyalkylene oxides covalently bonded thereto by a linkage formed by reacting the nucleophile with an aryl imidate activated polyalkylene oxide.

The biologically active conjugates of the present invention possess numerous therapeutic applications. The present invention therefore also provides a method of treatment in which a mammal in need thereof is administered a therapeutically effective amount of the biologically active conjugates of the present invention.

The hydrolytic stability of the aryl imidate activated polyalkylene oxides of the present invention permit bulk solutions of activated polyalkylene oxide to be prepared in advance of production runs. Furthermore, the aryl imidate group can be reacted with a variety of biologically active nucleophiles of interest other than lysine epsilon amino groups of polypeptides. For example, the aryl imidates will react with any polypeptide nucleophile, including cysteine mercapto groups.

In addition, the aryl imidates are also reactive with nucleotides such as guanine, adenine, and the like, and derivatives thereof which possess nucleophilic amino groups.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The aryl imidate activated polyalkylene oxides of the present invention must be prepared from polyalkylene oxides that are soluble in water at room temperature. Polyalkylene oxides meeting this requirement are polyethylene glycol (PEG) and copolymers thereof. Block copolymers of PEG with polypropylene glycol or polypropylene oxide are also suitable for use with the present invention, provided that the degree of block copolymerization is not so great as to render the polymer insoluble in water at room temperature.

The molecular weight of the polymer will depend mainly upon the end use of a particular polymer conjugate. Those of ordinary skill in the art are capable of determining molecular weight ranges suitable for their end-use applications.

In general, the useful range of molecular weight is a number average molecular weight between about 600 and about 100,000 daltons, and preferably between about 2,000 and about 20,000 daltons. A molecular weight of 5,000 daltons is most preferred.


Preferred aryl imidate activated polyalkylene oxides are represented by the structure of Formula I, wherein R is a water-soluble polyalkylene oxide, L is a moiety forming a hydrolytically stable, covalently bonded linkage between the polyalkylene oxide and the phenyl ring of the arylimidate, R₁ is a moiety selected from alkyl, phenyl, phenylalkyl, cycloalkyl, and the like, and X is a terminal moiety of the polyalkylene oxide.

The aryl imidate activated polyalkylene oxides of the present invention, including those depicted by Formula I, are usually recovered in the form of an imidate salt, typically a hydrochloride or hydrobromide salt. Therefore, the polyalkylene oxide aryl imidates of

the present invention are defined as including the imide salts thereof.

X can be a group into which a terminal hydroxyl group may be converted, including the reactive derivatives of the prior art disclosed in U.S. Patent Nos. 4,179,337, 4,847,325, 5,122,614 and in copending and commonly owned U.S. Patent Application Serial No. 626,696, filed March 18, 1991, the disclosures of all of which are hereby incorporated herein by reference thereto. The heterobifunctional polymers can be prepared by methods known to those skilled in the art without undue experimentation.

X can thus also be an aryl imide derivative having the structure of Formula II:



wherein L and R₁ are the same as disclosed above with respect to Formula I.

20 When the moieties selected for L and R₁ on both ends of the polymer are identical, the polymer will then be a symmetrical, homobifunctional polymer derivative.

25 Such double polymer substitution can result in either intra- or intermolecular crosslinking of the nucleophile, which, in some cases, can be useful. Such crosslinking can be controlled by the amount of polymer used and the concentration of reacting species, which methods are well-known to those of ordinary skill in the art.

30 Crosslinking can also be prevented by using a pre-block polymer having only one labile hydroxyl group per polymer moiety. In such polymers, X would represent a blocking group such as an alkoxy group of one to four

carbon atoms.

The preferred blocking group is a methoxy group. For the preparation of homobifunctional and monofunctional polymer derivatives, see Buckmann et al.,
5 Makromol. Chem., 182(5), 1379-84 (1981). X can also represent an antibody or solid support covalently coupled to the polymer by methods known to those skilled in the art as illustrated in EP 295,073.

The moieties represented by L that are capable of
10 forming a hydrolytically stable covalently bonded linkage between a polyalkylene oxide and the phenyl ring of an aryl imidate are well-known to those of ordinary skill in the art. Examples of L include $-R_2-$ and $-R_2-(CH_2)_Z-R_3-$, wherein Z is an integer from one to six, inclusive, and
15 R_2 and R_3 are moieties independently selected from amide, urea, urethane, ether, secondary amine and imidate moieties.

The aryl imidate activated polyalkylene oxides of the present invention are formed by reacting a
20 benzonitrile-capped polyalkylene oxide with an alcohol in the presence of anhydrous hydrogen chloride gas. For example, to obtain the aryl imidate activated polyalkylene oxide of Formula I, an alcohol represented by the formula R_1OH , wherein R_1 is the same as described
25 above with respect to Formula I is reacted with a benzonitrile capped polyalkylene oxide represented by the structure of Formula III:



30

wherein R, L and X are the same as described above with respect to Formula I.

The resulting aryl imidate has improved hydrolytic stability, but yet is capable of undergoing nucleophilic

displacement of the $-OR_i$ moiety. R_i is preferably a methyl, ethyl, phenyl, benzyl or cyclohexyl moiety.

The reaction is carried out in a solvent in which the reactants are soluble, such as methanol. A reaction temperature between 0°C and 10°C is suitable, and a temperature between 5°C and 8°C is preferred. All materials must be essentially free of water. Scrupulous care must be taken not to contaminate the reaction mixture with water.

The benzonitrile capped polyalkylene oxides of the present invention are formed by reacting a polyalkylene oxide or a functionalized polyalkylene oxide with a substituted benzonitrile. Other reactants may also be required. The selection of a polyalkylene oxide, functionalized polyalkylene oxide, substituted benzonitrile, and other reactants to obtain the desired L group is well understood by those of ordinary skill in the art.

For example, a urethane linkage can be obtained for L by reacting a polyalkylene oxide with a benzonitrile isocyanate. A urethane group can also be obtained by reacting a polyalkylene oxide isocyanate with a hydroxy benzonitrile.

Polyalkylene oxide isocyanates are obtained by reacting polyalkylene oxide amines, which are commercially available, with phosgene. A diurethane linkage can be obtained for L by reacting an alkyl diisocyanate such as hexamethylene diisocyanate, with a polyalkylene oxide and a hydroxybenzonitrile.

A two-step reaction familiar to those skilled in the art is required to prevent double polyalkylene oxide or double hydroxybenzonitrile substitution of the diisocyanate. The polyalkylene oxide is added to an excess of diisocyanate, so that an isocyanate capped

polyalkylene oxide is formed as the predominant reaction product from which the significantly lower molecular weight unreacted diisocyanate is readily removed. The isocyanate capped polyalkylene oxide is then reacted with the hydroxy benzonitrile.

An ether or secondary amine linkage can be obtained for L by reacting a polyalkylene oxide substituted with a moiety capable of undergoing nucleophilic displacement in the presence of a base with a hydroxy or amino benzonitrile.

Polyalkylene oxide tosylates are preferred, which are prepared by reacting polyalkylene oxides with toluenesulfonyl chloride in a well-known reaction. See, e.g., the procedure of Mutter, Tetrahedron Lett., 31, 2839-42 (1978). Other suitable polyalkylene oxides are polyalkylene oxide mesylates and polyalkylene oxide triflates which are prepared similarly. The ether linkage is formed by reacting the substituted polyalkylene oxide with hydroxybenzonitrile, and the secondary amine linkage is formed by reacting the activated polyalkylene oxide with aminobenzonitrile.

The formation of an amide linkage for L is also essentially conventional and can be obtained by reacting polyalkylene oxide amines, which are commercially available, with carboxybenzonitriles, or by reacting polyalkylene oxide carboxylic acids with aminobenzonitriles. Polyalkylene oxide carboxylic acid chlorides are commercially available (Aldrich Chemical) and can also be prepared by the method disclosed by Buckmann et al., Makromol. Chem., 182(5), 1379-84 (1981). The acid chloride is readily converted to the carboxylic acid by well-known, conventional methods. Diamide linkages can be formed by reacting alkyl diamines with polyalkylene oxide carboxylic acids and

carboxybenzonitriles using the above-described two-step reaction, or by reacting polyalkylene oxide amines and aminobenzonitriles with a dicarboxylic acid such as malonic acid, succinic acid, glutaric acid, maleic acid, fumaric acid or phthalic acid.

The diamide can also be formed by reacting the polyalkylene oxide amines and aminobenzonitriles with an acid anhydride such as succinic anhydride, maleic anhydride or phthalic anhydride, again using a two-step reaction. The carboxylic acids, dicarboxylic acids or acid anhydrides should either first be converted to acid chlorides, or else reacted with the amines or diamines in a carbodiimide mediated coupling reaction.

The formation of a urea linkage for L is obtained by reacting a polyalkylene oxide amine with a benzonitrile isocyanate, or by reacting a polyalkylene oxide isocyanate with an aminobenzonitrile. Diurea linkages can be formed by reacting alkyl diisocyanates with polyalkylene oxide amines and aminobenzonitriles using the above-described two-step reaction, or by reacting polyalkylene oxide isocyanates and benzonitrile isocyanates with an alkyl diamine, again using a two-step reaction.

The stoichiometry and reaction conditions for attaching the benzonitriles to the polyalkylene oxides are well understood and essentially conventional. The reactions are carried out in solvents in which the reactants are soluble, such as methanol. Reaction temperatures between 0°C and 10°C are suitable, and temperatures between 5°C and 8°C are preferred. Again, all materials must be essentially water-free.

The adaption of the above reactions to obtain a bifunctional polyalkylene oxide is also well understood by one of ordinary skill in the art. (See, Buckmann et

al., Makromol. Chem.) Meta- and para-substituted benzonitriles are suitable for use with the present invention, although para-substituted benzonitriles are preferred because they are commercially available.

5 The aryl imidate activated polyalkylene oxides are purified from low molecular weight materials by conventional methods. The polyalkylene oxide aryl imidate can then be reacted with biologically active nucleophiles to form a linkage between the polyalkylene
10 oxide and the biologically active nucleophile. The resulting product represents a biologically active conjugate of the nucleophile and the polyalkylene oxide.

15 The term "hydrolytically stable" means that the aryl imidates of the present invention, in aqueous solution, will not undergo substantial degradation at physiological pH up to 27°C. Degradation of less than 50% under these conditions over an eight hour time period is considered insubstantial. At 4°C, substantially less degradation is expected.

20 The term "biologically active" is used with respect to the nucleophiles of the present invention consistently with the meaning commonly understood to those of ordinary skill in the art, which meaning is not limited to physiological or pharmacological activities of the
25 nucleophiles in the therapeutic sense. For example, many physiologically active nucleotides such as enzymes, the polyalkylene oxide conjugates of which may not have therapeutic applications, are able to catalyze reactions in organic solvents. Likewise, regardless of the
30 therapeutic uses for polyalkylene oxide conjugates of proteins such as concanavalin A, immunoglobulins, and the like, the polyalkylene oxide conjugates of these proteins are also useful as laboratory diagnostic tools.

 The polyalkylene oxide conjugates of the

biologically active nucleophiles of the present invention are biologically active and possess numerous therapeutic applications. Mammals in need thereof may be treated by administering a therapeutically effective amount of the biologically active polyalkylene oxide conjugates of the biologically active nucleophiles of the present invention.

Therefore, the biologically active nucleophiles of interest to the present invention include a variety of enzymes, including, but not limited to, carbohydrate-specific enzymes, proteolytic enzymes, and the like. Enzymes of interest, for both biological applications in general and therapeutic applications in particular include the oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases disclosed by U.S. Patent No. 4,179,337, the disclosure of which is hereby incorporated herein by reference thereto. Without being limited to particular enzymes, examples of specific enzymes of interest include asparaginase, arginase, adenosine deaminase, superoxide dismutase, catalase, chymotrypsin, lipase, uricase and bilirubin oxidase. Carbohydrate-specific enzymes of interest include glucose oxidase, glucosidase, galactosidase, glucocerebrosidase, glucuronidase, etc.

The biologically active nucleophiles of the present invention also include proteins of general biological or therapeutic interest, including, but not limited to, hemoglobin and serum proteins such as Factor VIII, Factor IX, immunoglobulins, lectins, interleukins, interferons and colony stimulating factors, and ovalbumin and bovine serum albumin (BSA). Other proteins of general biological or therapeutic interest include hormones such as insulin, ACTH, glucagon, somatostatin, somatotropins, thymosin, parathyroid hormone, pigmentary hormones,

somatomedins, erythropoietin, luteinizing hormone, hypothamic releasing factors, antidiuretic hormones, prolactin, chorionicgonadotropin, follicle-stimulating hormone, thyroid-stimulating hormone, tissue plasminogen activator, and the like. Immunoglobulins of interest include IgG, IgE, IgM, IgA, IgD and fragments thereof.

Certain of the above proteins such as the interleukins, interferons and colony stimulating factors also exist in non-glycosilated form, usually the result of preparation by recombinant protein techniques. The non-glycosilated versions are also among the biologically active nucleophiles of the present invention.

Other proteins of interest are allergen proteins disclosed by Dreborg et al., Crit. Rev. Therap. Drug Carrier Syst., 6, 315-65 (1990) as having reduced allergenicity when conjugated with polyalkylene oxides, and consequently suitable for use as tolerance inducers. Among the allergins disclosed are Ragweed Antigen E, honeybee venom, mite allergen, and the like.


Other biologically active nucleophiles of the present invention include oligonucleotides, the coupling of which to polyalkylene oxides is disclosed by the above-cited U.S. Patent No. 4,904,582, and therapeutically active nucleophilic compounds, such as the dihydropyridine calcium channel blockers, the coupling of which with polyalkylene oxides is disclosed by the above-cited U.S. Patent No. 5,160,734.

One or more polyalkylene oxides can be attached covalently to the biologically active nucleophile by reacting the aryl imidate activated polyalkylene oxide with the nucleophile. The aryl imidate reacts with the nucleophile to form a linkage covalently bonding the nucleophile to the polyalkylene oxide. When the nucleophile is a protein or polypeptide, conjugation

occurs at the ϵ -NH₂ moieties of lysines to form linkages containing stable amidate moieties.

For nucleophiles such as polypeptides, more than one polyalkylene oxide conjugate per nucleophile is preferred. The degree of conjugation is limited only by the number of available ϵ -NH₂ moieties of lysines. The optimum degree of conjugation can be readily determined for a particular nucleophile by one of ordinary skill in the art without undue experimentation. The degree of conjugation may be modified by varying the reaction stoichiometry by well-known techniques.

The reaction of aryl imidate activated polyalkylene oxides with the epsilon-NH₂ moieties of polypeptide lysines to form an amidate linkage is illustrated by the reaction sequence depicted below in which R, L, X and R₁ are the same as described above with respect to Formula I and R₄ represents the balance of the polypeptide:



The biologically active nucleophiles may be reacted directly with the aryl imidate activated polyalkylene oxides in an aqueous reaction medium. This reaction medium may also be buffered, depending upon the pH requirements of the nucleophile. The optimum pH for the reaction is generally between about 6.5 and about 8.0 and preferably about 7.4.

In all instances, the optimum reaction medium pH for the stability of particular nucleophiles and for reaction

efficiency, and the buffer in which this can be achieved, is readily determined within the above ranges by those of ordinary skill in the art without undue experimentation. For purposes of this application, the operativeness of the within reactions under mild conditions is defined as meaning that the preferred temperature range is between about 4 and about 37°C.

Those of ordinary skill in the art will understand that the reactions will run somewhat faster to completion at higher temperatures, with the proviso that the temperature of the reaction medium cannot exceed the temperature at which the nucleophile may denature or decompose. Furthermore, those of ordinary skill in the art will understand that certain nucleophiles, particularly polypeptides, will require reaction with the aryl imidate activated polyalkylene oxides at reduced temperatures to minimize loss of activity and/or to prevent denaturing. The reduced temperature required by particular polypeptides is preferably no lower than 4°C and in no event should this temperature be lower than 0°C. The reaction will still take place, although longer reaction times may be necessary.

Usually, the nucleophile is reacted in aqueous solution with a quantity of the aryl imidate activated polyalkylene oxide in excess of the desired degree of conjugation. Following the reaction, the conjugated product is recovered and purified by diafiltration, column chromatography or the like.

In view of the foregoing, it can be readily appreciated that the aryl imidate activated polyalkylene oxides of the present invention possess the optimum balance of reactivity and hydrolytic stability so that polymer conjugates can be formed with biologically active nucleophiles with an insubstantial amount of hydrolytic

degradation of the activated polyalkylene oxide. Thus, reaction yields are increased and process costs are reduced.

The following non-limiting examples set forth hereinbelow illustrate certain aspects of the invention. All parts and percentages are by weight unless otherwise noted, and all temperatures are in degrees Celsius.

EXPERIMENTAL

Example 1

Synthesis Of m-PEG Aryl Imidate

An aryl imidate activated PEG of Formula I, in which L is -NH-CO- , is prepared by first adding to a clean, dry 250 mL three-neck flask 1.0 g (1.99×10^{-4} mole) of m-PEG amine and 200 mL of toluene. The solution is heated, with stirring, to 110°C to remove water along with 100 mL of toluene. The solution is cooled to 25°C and 0.056 mL (0.040 g, 3.99×10^{-4} mole) of triethylamine is added, followed by 0.33 g (1.99×10^{-3} mole) of 4-cyanobenzoyl chloride.

The mixture is heated at $75\text{-}80^{\circ}\text{C}$ for four hours, cooled to 40°C and filtered through a glass filter while warmed to remove triethylamine hydrochloride. As much toluene as possible is stripped off via rotary evaporation, after which 200 mL of isopropanol is added to the residue, followed by heating to 50°C with stirring to dissolve. This solution is then cooled to room temperature with stirring to effect precipitation. The precipitate is collected by filtration, washed with 100 mL of isopropanol and dried in a vacuum oven at 4°C .

100 mL anhydrous methanol is added to a clean, dry 300 mL three-neck round bottomed flask and cooled to

-10°C by means of a dry ice bath. HCl gas is added subsurface to the methanol with stirring until it is saturated. 1.0 g of the product from the previous step is dissolved in 2 mL of methylene chloride, which solution is then added to the methanolic HCl with stirring. The reaction mixture is allowed to warm to room temperature and held for eight hours. 150 mL of cold ethyl ether is added to the flask to induce precipitation of the m-PEG aryl imidate. The product is collected by filtering the cold mixture and washing with 10 mL of ethyl ether. The product is then dried in a dessicator at room temperature.

Example 2

Conjugation Of Bovine Hemoglobin With m-PEG Aryl Imidate

The aryl imidate activated m-PEG of Example 1 is conjugated with bovine hemoglobin by first preparing a 10 mL solution of pH 7.8 phosphate buffer by dissolving 0.1380 g $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$, 0.2681 g $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ and 0.2338 g NaCl in 7.0 mL deionized water. The pH of the solution is then adjusted to 7.8 with 1.0 N NaOH and diluted to 10 mL with deionized water. A 4.0 mL sample of isolated bovine hemoglobin (10.9%, 7.02×10^{-6} mole) is measured into a 50 mL jacketed beaker chilled to 8°C by means of a refrigerated recirculating bath. A thermometer and pH electrode are placed in the hemoglobin, which is stirred magnetically. The pH of the hemoglobin is adjusted to 7.8 with 1.0 N NaOH where 1.0 N HCl as necessary.

To this is added 0.6515 g of the m-PEG aryl imidate of Example 1 (1.26×10^{-4} mole) followed by 4.0 mL of the pH 7.8 phosphate buffer prepared above. The mixture is stirred at 8°C for one hour while maintaining pH 7.8 with dropwise additions of 1.0 N NaOH or 1.0 N HCl. After one

hour of reaction time, 0.0420 g (2.39×10^{-4} mole) of cysteine.HCl is added, followed by 0.0095 g (1.26×10^{-4} mole) of glycine. The pH is adjusted up to 7.8 using 1.0 N NaOH, and the mixture is allowed to stir for 15 minutes. The resulting conjugate of m-PEG and hemoglobin is then stored in a 4°C refrigerator.

As will be readily appreciated, numerous variations and combinations of the features set forth above can be utilized without departing from the present invention as set forth in the claims. Such variations are not regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be included within the scope of the following claims.

WHAT IS CLAIMED IS:

1. A water-soluble aryl imidate activated polyalkylene oxide.

2. The aryl imidate activated polyalkylene oxide of claim 1, wherein said polyalkylene oxide is selected from the group consisting of polyethylene glycol and block copolymers of polyethylene glycol and polypropylene glycol.


3. The aryl imidate activated polyalkylene oxide of claim 2, wherein said polyalkylene oxide comprises polyethylene glycol.

4. The aryl imidate activated polyalkylene oxide of claim 1, wherein said polyalkylene oxide has a number average molecular weight between about 600 and about 100,000 daltons.

5. The aryl imidate activated polyalkylene oxide of claim 4, wherein said polyalkylene oxide has a number average molecular weight between about 2,000 and about 20,000 daltons.

6. The aryl imidate activated polyalkylene oxide of claim 5, wherein said polyalkylene oxide has a 5,000 dalton number average molecular weight.

7. The aryl imidate activated polyalkylene oxide of claim 1, having a structure represented by:



wherein R is a water-soluble polyalkylene oxide;

L is a moiety forming a hydrolytically stable, covalently bonded linkage between said polyalkylene oxide and the phenyl ring of the aryl imidate moiety;

5 R_1 is a moiety selected from the group consisting of alkyl, phenyl, phenylalkyl and cycloalkyl moieties; and

X is a terminal moiety of said polyalkylene oxide.


8. The aryl imidate activated polyalkylene oxide of claim 7, wherein L comprises a moiety represented by $-R_2-$ or $-R_2-(CH_2)_Z-R_3-$, wherein Z is an integer from one to six, inclusive, and R_2 and R_3 are moieties independently selected from the group consisting of amide, urea, urethane, ether, secondary amine and imidate moieties.

15 9. The aryl imidate activated polyalkylene oxide of claim 7, wherein R_1 is a moiety selected from the group consisting of methyl, ethyl, phenyl, benzyl and cyclohexyl moieties.

20 10. The aryl imidate activated polyalkylene oxide of claim 7, wherein X is a moiety selected from the group consisting of alkoxy moieties containing up to four carbon atoms.

25 11. The aryl imidate activated polyalkylene oxide of claim 10, wherein X is a methoxy moiety.

30 12. The aryl imidate activated polyalkylene oxide of claim 7, wherein X has a structure corresponding to:



13. A polyalkylene oxide conjugate comprising:
a nucleophile having biological activity; and
at least one water-soluble polyalkylene oxide
covalently bonded thereto by a hydrolytically stable
5 linkage formed by reacting said nucleophile with an aryl
imidate activated polyalkylene oxide.

14. The polyalkylene oxide conjugate of claim 13,
wherein said polyalkylene oxide is selected from the
10 group consisting of polyethylene glycol and block
copolymers of polyethylene glycol and polypropylene
glycol.

15. The polyalkylene oxide conjugate of claim 14,
15 wherein said polyalkylene oxide comprises polyethylene
glycol.

16. The polyalkylene oxide conjugate of claim 13,
wherein said polyalkylene oxide has a number average
20 molecular weight between about 600 and about 100,000
daltons.

17. The polyalkylene oxide conjugate of claim 16,
wherein said polyalkylene oxide has a number average
25 molecular weight between about 2,000 and about 20,000
daltons.

18. The polyalkylene oxide conjugate of claim 17,
wherein said polyalkylene oxide has a 5,000 dalton number
30 average molecular weight.

19. The polyalkylene oxide conjugate of claim 13,
wherein said nucleophile is an enzyme selected from the
group consisting of asparaginase, arginase, adenosine

deaminase, superoxide dismutase, catalase, chymotrypsin, lipase, uricase, bilirubin oxidase, glucose oxidase, glucosidase, galactosidase, glucocerebrosidase and glucuronidase.

5

20. The polyalkylene oxide conjugate of claim 13, wherein said nucleophile is a serum protein selected from the group consisting of Factor VIII, Factor IX, interleukins, interferons, colony stimulating factors, immunoglobulins and lectins.

10

21. The polyalkylene oxide conjugate of claim 20, wherein said nucleophile is an immunoglobulin selected from the group consisting of IgG, IgE, IgM, IgA, IgD and fragments thereof.

15

22. The polyalkylene oxide conjugate of claim 13, wherein said nucleophile is a hormone selected from the group consisting of insulin, ACTH, glucagon, somatostatin, somatotropins, thymosin, parathyroid hormone, pigmentary hormones, somatomedins, erythropoietin, luteinizing hormone, hypothalamic releasing factors, antidiuretic hormones, prolactin, chorionic gonadotropin, follicle stimulating hormone, tissue plasminogen activator and thyroid-stimulating hormone.

20


25

23. The polyalkylene oxide conjugate of claim 13, wherein said nucleophile is a protein selected from the group consisting of hemoglobin, ovalbumin and bovine serum albumin.


30

24. The polyalkylene oxide conjugate of claim 13, wherein said nucleophile is a polypeptide comprising lysine residues, and at least one of said polyalkylene oxides is covalently bonded to the epsilon-NH₂ moiety of said lysine residue via a linkage forming an amidate moiety with said epsilon-NH₂ moiety.

25. The polyalkylene oxide conjugate of claim 24, wherein said polypeptide has a structure represented by:



wherein -NH₂ is a lysine epsilon NH₂ moiety and R₄ and R₅ represent the balance of said polypeptide, and said polyalkylene oxide conjugate has a structure represented by:



wherein R is a water-soluble polyalkylene oxide;

L is moiety forming a hydrolytically stable, covalently bonded linkage between said polyalkylene oxide and the phenyl ring of the aryl imidate moiety; and

X is a terminal moiety of said polyalkylene oxide.

26. The polyalkylene oxide conjugate of claim 25, wherein L comprises a moiety represented by -R₂- or -R₂-(CH₂)_Z-R₃-, wherein Z is an integer from one to six, inclusive, and R₂ and R₃ are moieties independently selected from the group consisting of amide, urea, urethane, ether, secondary amine and imidate moieties.


25

27. The polyalkylene oxide conjugate of claim 25, wherein X is a moiety selected from the group consisting of alkoxy moieties containing up to four carbon atoms.

5 28. The polyalkylene oxide conjugate of claim 27, wherein X is a methoxy moiety.

29. The polyalkylene oxide conjugate of claim 25, wherein X has a structure corresponding to:

10



15 30. The polyalkylene oxide conjugate of claim 13, comprising a plurality of polyalkylene oxides covalently bonded to said nucleophile.

20 31. A method of treatment comprising administering to a mammal in need thereof a therapeutically effective amount of the polyalkylene oxide conjugate of claim 13.

25 32. A method of forming a biologically active conjugate of a biologically active nucleophile and one or more water-soluble polyalkylene oxides covalently bonded thereto, said method comprising the steps of:

30 providing a biologically active nucleophile;
 contacting said nucleophile with one or more aryl imidate activated polyalkylene oxides, so that a biologically active conjugate of said biologically active nucleophile and said polyalkylene oxides is formed; and
 recovering said biologically active conjugate.


26

33. A process for the preparation of an aryl imidate activated polyalkylene oxide, said process comprising the steps of:

5 reacting a benzonitrile-capped polyalkylene oxide with an alcohol in the presence of anhydrous hydrogen chloride gas, so that an aryl imidate activated polyalkylene oxide is formed; and

10 recovering said aryl imidate activated polyalkylene oxide.

34. The process of claim 33, wherein said alcohol has the formula R_1OH , said benzonitrile-capped polyalkylene oxide has a structure represented by:



and said aryl imidate activated polyalkylene oxide has a structure represented by:



25 wherein R is a water-soluble polyalkylene oxide;

L is a moiety forming a hydrolytically stable, covalently bonded linkage between said polyalkylene oxide and the phenyl ring of said benzonitrile and said aryl imidate moiety;

30 R_1 is a moiety selected from the group consisting of alkyl, phenyl, phenylalkyl and cycloalkyl moieties; and

X is a terminal moiety of said polyalkylene

oxide.

35. The process of claim 34, wherein said benzonitrile-capped polyalkylene oxide polyalkylene oxide
5 is formed by reacting a polyalkylene oxide or a functionalized polyalkylene oxide with a substituted benzonitrile, wherein said polyalkylene oxide or functionalized polyalkylene oxide and said substituted benzonitrile are capable of reacting to form said
10 hydrolytically stable linkage, L, covalently linking said polyalkylene oxide with said phenyl ring of said benzonitrile.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/12480

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :C07C 249/00,263/00

US CL :558/6

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 558/6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN/CAS, CSIR/APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,179,337 (Davis et al) 18 December 1979, see column 2, lines 25-39.	1-1-35
A	US, A, 4,492,657 (Heiss) 08 January 1985, see column 1 lines 5-10.	1-12 and 33-35
A	US, A, 5,109,120 (Ueno et al) 28 April 1992, see column 2 lines 1-11.	1-32
A	US, A, 4,791,192 (Nakagawa et al) 13 December 1988, see column 3, lines 27-36.	1-32
A	US, A, 5,122,614 (Zalipsky) 16 June 1992, see column 4, line 50.1-32	1-32

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be part of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 March 1994

Date of mailing of the international search report

APR 05 1994

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. 703-305-3230

Authorized officer

KEITH MACMILLAN

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/12480

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 5,160,734 (Genesan et al) 03 November 1992, see column 2, lines 35-40.	1-32
A	US, A, 4,904,582 (Tullis) 27 February 1990, see column 4, line 65.	1-32